Haemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.

Link to 4Q Earnings Release

GUIDANCE:

Haemonetics sees FY2022 EPS of $2.60-$3.00, versus the consensus of $2.56.

For earnings history and earnings-related data on Haemonetics (HAE) click here.